Nomura: Maintains JD HEALTH "Buy" Rating and Raises Target Price to HKD 41.5
Nomura released a research report stating that it maintains a "Buy" rating on JD HEALTH, raising the target price from HKD 31 to HKD 41.5, and increasing the revenue forecasts for JD HEALTH for the fiscal years 2025 and 2026 by 2% and 3% respectively. JD HEALTH's revenue in the second half of the fiscal year 2024 grew by 13% year-on-year, exceeding both market and the bank's forecasts by 1%; the non-International Financial Reporting Standards operating profit margin increased by 0.4 percentage points to 3.4%, surpassing the bank's forecast by 0.2 percentage points; the non-International Financial Reporting Standards net profit grew by 27% year-on-year, exceeding market and the bank's estimates by 15% and 6% respectively
According to the Zhitong Finance APP, Nomura has released a research report maintaining a "Buy" rating for JD HEALTH (06618), raising the target price from HKD 31 to HKD 41.5, and increasing the revenue forecasts for JD HEALTH for the fiscal years 2025 and 2026 by 2% and 3% respectively. JD HEALTH's revenue in the second half of the fiscal year 2024 grew by 13% year-on-year, exceeding both market and the bank's forecasts by 1%; the non-International Financial Reporting Standards operating profit margin increased by 0.4 percentage points to 3.4%, surpassing the bank's forecast by 0.2 percentage points; the non-International Financial Reporting Standards net profit grew by 27% year-on-year, exceeding market and the bank's estimates by 15% and 6% respectively
